AP26113 is a potent inhibitor targeting ALK (anaplastic lymphoma kinase) and ROS1 tyrosine kinases, primarily used in the treatment of non-small cell lung cancer (NSCLC) that exhibits ALK or ROS1 gene rearrangements. It demonstrates strong activity against both wild-type and mutant forms of ALK, including the common resistance mutation L1196M, making it effective in patients who have progressed on earlier-generation ALK inhibitors. Due to its ability to penetrate the blood-brain barrier, AP26113 shows significant efficacy in controlling central nervous system metastases, a common challenge in advanced NSCLC. Its dual inhibition of ALK and ROS1 expands its therapeutic use across different molecular subtypes of lung cancer, supporting its role in personalized oncology treatment strategies.